Epidemiology of liver cancer in Europe

Canadian Journal of Gastroenterology

Volumn 14, Issue 7, 2000, Pages 621-630

  Bosch, F X ^a   Ribes, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Europe; Hepatitis B virus; Hepatitis C virus; Liver cancer

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS C VACCINE; ORAL CONTRACEPTIVE AGENT; VIRUS DNA; VIRUS RNA;

AFRICA; ALCOHOL CONSUMPTION; ASIA; CANCER INCIDENCE; CANCER MORTALITY; CENTRAL AMERICA; CIGARETTE SMOKING; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EUROPE; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION; JAPAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MUTATION; PACIFIC ISLANDS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0033825771     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/815454     Document Type: Review

References (111)

1. Estimates of the worldwide incidence of 25 major cancers in 1990
2. Estimates of the worldwide mortality from 25 cancers in 1990
3. Cancer mortality among sub-Saharan African migrants in France
4. Cancer in mediterranean migrants - Based on studies in France and Australia
5. Cancer mortality in Indian and British ethnic immigrants from the Indian subcontinent to England and Wales
6. Cancer mortality in African and Caribbean migrants to England and Wales
7. Cancer mortality in Italian migrants to Canada
8. Characteristics of hepatocellular carcinoma in Italy
9. Trends in primary liver cancer
10. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995
11. Oral contraceptives and primary liver cancer: Temporal trends in three countries
12. Changing incidence of hepatocellular carcinoma in Japan
13. Hepatitis C virus and hepatocellular carcinoma
14. Modeling the hepatitis C virus epidemic in France
15. Epidemiology of primary liver cancer
16. Risk factors for hepatocellular carcinoma among Japanese women
17. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma
18. Hepatitis B virus and liver cancer - Unanswered questions
19. Viral hepatitis and liver cancer
20. Hepatocellular carcinoma
21. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma
22. Cancer and infection: Estimates of the attributable fraction in 1990
23. Hepatitis C: Global prevalence
24. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis
25. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma
26. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma
27. A case-control study in GB virus C/hepatitis G virus infection and hepatocellular carcinoma
28. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy
29. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action
30. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis
31. High frequency of antibodies to the hepatitis C virus among patients with hepatocellular carcinoma
32. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease
33. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitis C virus peptides
34. A case-control study of hepatitis B and C virus infections in the aetiology of hepatocellular carcinoma
35. The leading role of hepatitis B and C viruses as risk factors for the development of hepatocellular carcinoma A case control study
36. Hepatitis-C-virus und hepatom
37. Hepatitis C virus, alcoholic cirrhosis, and hepatocellular carcinoma
38. Association between chronic hepatitis C infection and hepatocellular carcinoma in a scottish population
39. Progression of hepatitis B and C to hepatocellular carcinoma in western countries
40. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma
41. Quantitation of hepatitis G and C viruses in the liver: Evidence that hepatitis G virus is not hepatotropic
42. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease
43. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
44. Alcohol and hepatocellular carcinoma
45. Risk factors for hepatocellular carcinoma in Catalonia, Spain
46. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study
47. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study
48. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus
49. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma
50. Oral contraceptives and cancer
51. Trends in mortality from primary liver cancer in England and Wales 1975-92: Influence of oral contraceptives
52. Prospects for epidemiological studies on hepatocellular cancer as model for assessing viral and chemical interactions
53. Non association of aflaxotin with primary liver cancer in a cross-sectional ecological survey in the People's of Republic of China
54. Hepatocellular carcinoma: From gene to public health
55. Cancer risk following primary hemochromatosis: A population-based cohort study in Denmark
56. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of Multiple-Cause Mortality Data
57. Body iron stores and the risk of cancer
58. Body iron stores and risk of cancer
59. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors
60. Screening for hemochromatosis in primary care settings
61. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis
62. Putting a hold on 'HLA-H'. The WHO Nomenclature Committee for Factors of the HLA System
63. Excess risk of primary liver cancer in patients with diabetes mellitus
64. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark
65. Diabetes mellitus and the risk of primary liver cancer
66. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates
67. Hepatitis C infection and viremia in Dutch hemophilia patients
68. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C UK. Haemophilia Centre Directors' Organisation
69. Epidemiology of hepatitis B virus infections among injecting drug users: Seroprevalence, risk factors, and viral interactions
70. Mortality of drug addicts in the United Kingdom 1967-1993
71. Mortality among drug users in the AIDS era
72. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
73. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
74. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
75. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?
76. Immunosurveillance and cancer: Epidemiologic observations
77. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgG subclass deficiency
78. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contamined immune globulin
79. Hepatitis C viral infection in the immunosuppressed patient
80. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease
81. Type, prevalence and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease
82. Cancer incidence and mortality in a cohort of chloroprene workers from Armenia
83. Cancer mortality among Moscow shoes workers exposed to chloroprene (Russia)
84. Identification of occupational carcinogens
85. Occupational cancer risk associated with the storage and bulk handling of agricultural foodstuff
86. Family history and the risk of liver, gallbladder, and pancreatic cancer
87. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency of hepatocellular carcinoma
88. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages
89. Efficacy of a mass hepatitis B vaccination program in Taiwan
90. Prospects for prevention of Hepatitis types B and C in North America
91. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children, Taiwan Childhood Hepatoma Study Group
92. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea
93. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial
94. Syringe exchange and risk of infection with hepatitis B and C viruses
95. Reduced risk of hepatitis B and C among participants in a syringe exchange program
96. The role of tobacco use and alcohol consumption in the aetiology of hepatocellular carcinoma
97. Smoking as a risk factor in hepatocellular carcinoma. A case-control study in Southern African blacks
98. Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case-control study in South African black women